CN110382501A - 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法 - Google Patents

用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法 Download PDF

Info

Publication number
CN110382501A
CN110382501A CN201780086584.0A CN201780086584A CN110382501A CN 110382501 A CN110382501 A CN 110382501A CN 201780086584 A CN201780086584 A CN 201780086584A CN 110382501 A CN110382501 A CN 110382501A
Authority
CN
China
Prior art keywords
alkyl
aryl
heteroaryl
independently
unit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780086584.0A
Other languages
English (en)
Chinese (zh)
Inventor
B·梅科嫩
J·A·布特拉
黄建星
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agenebio Inc
Original Assignee
Agenebio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenebio Inc filed Critical Agenebio Inc
Priority to CN202310213936.1A priority Critical patent/CN116640143A/zh
Publication of CN110382501A publication Critical patent/CN110382501A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN201780086584.0A 2016-12-19 2017-12-20 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法 Pending CN110382501A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310213936.1A CN116640143A (zh) 2016-12-19 2017-12-20 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662436272P 2016-12-19 2016-12-19
PCT/IB2017/001762 WO2018130868A1 (en) 2016-12-19 2017-12-20 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310213936.1A Division CN116640143A (zh) 2016-12-19 2017-12-20 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法

Publications (1)

Publication Number Publication Date
CN110382501A true CN110382501A (zh) 2019-10-25

Family

ID=62557208

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310213936.1A Pending CN116640143A (zh) 2016-12-19 2017-12-20 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
CN201780086584.0A Pending CN110382501A (zh) 2016-12-19 2017-12-20 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202310213936.1A Pending CN116640143A (zh) 2016-12-19 2017-12-20 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法

Country Status (10)

Country Link
US (2) US20180170941A1 (enExample)
EP (1) EP3555100B1 (enExample)
JP (1) JP7153938B2 (enExample)
CN (2) CN116640143A (enExample)
AU (1) AU2017393082B2 (enExample)
CA (1) CA3047684A1 (enExample)
EA (1) EA201991497A1 (enExample)
IL (1) IL267451B2 (enExample)
MX (1) MX388726B (enExample)
WO (2) WO2018130868A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113413532A (zh) * 2021-07-01 2021-09-21 曾迎春 基于虚拟现实的癌症相关认知障碍评估与康复训练系统
CN115175911A (zh) * 2019-12-19 2022-10-11 艾吉因生物股份有限公司 用于治疗认知损害的苯二氮䓬衍生物、组合物和方法
CN116457019A (zh) * 2020-07-10 2023-07-18 艾吉因生物股份有限公司 GABAAα5激动剂的多晶型物及其在治疗认知损害中的使用方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX381561B (es) 2013-12-20 2025-03-12 Agenebio Inc Derivados de benzodiazepina, composiciones, y métodos para tratar el deterioro cognitivo.
US10815242B2 (en) 2015-06-19 2020-10-27 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CA3104478A1 (en) * 2018-06-19 2019-12-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2020072675A1 (en) 2018-10-02 2020-04-09 Northwestern University Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2c (5-ht2c)
AU2021304356A1 (en) * 2020-07-10 2023-02-23 Agenebio, Inc. Combinations of GABAA ALPHA 5 agonists and SV2A inhibitors and methods of using in the treatment of cognitive impairment
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5387585A (en) * 1991-06-17 1995-02-07 Hoffmann-La Roche Inc. Imidazodiazepine derivatives
CN1191255C (zh) * 2000-11-16 2005-03-02 弗·哈夫曼-拉罗切有限公司 作为gaba a受体调节剂的苯并二氮杂䓬衍生物
CN101044145A (zh) * 2004-10-20 2007-09-26 弗·哈夫曼-拉罗切有限公司 咪唑并－苯并二氮杂䓬衍生物
CN103327980A (zh) * 2010-11-15 2013-09-25 艾吉因生物股份有限公司 用于治疗认知障碍的苯并二吖庚因衍生物、组合物和方法
CN106068256A (zh) * 2013-12-20 2016-11-02 艾吉恩生物股份有限公司 用于治疗认知损害的苯并二氮杂*衍生物、组合物和方法
WO2016205739A1 (en) * 2015-06-19 2016-12-22 Belew Mekonnen Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
CA974518A (en) 1972-04-20 1975-09-16 Merz And Co. Procedure for the manufacture of 1,3,5 trisubstituted adamantan compounds
NL7605526A (nl) 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4816456A (en) 1986-10-01 1989-03-28 Summers William K Administration of monoamine acridines in cholinergic neuronal deficit states
HU201906B (en) 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
CA2000786C (en) 1988-11-07 1999-01-26 Cornelus G. M. Janssen 3-piperidinyl-1,2-benzisoxazoles
US5043345A (en) 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
DE10299048I2 (de) 1989-04-14 2006-07-13 Merz Pharma Gmbh & Co Kgaa Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie
ES2076253T3 (es) 1989-05-19 1995-11-01 Hoechst Roussel Pharma N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos.
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
JP2807577B2 (ja) 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
JP2800953B2 (ja) 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
US5190951A (en) 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
US5106856A (en) 1991-06-07 1992-04-21 Hoechst-Roussel Pharmaceuticals Inc. [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5763476A (en) 1994-03-02 1998-06-09 Akzo Noble N.V. Sublingual or buccal pharmaceutical composition
US6479523B1 (en) 1997-08-26 2002-11-12 Emory University Pharmacologic drug combination in vagal-induced asystole
WO2000051985A1 (en) 1999-03-03 2000-09-08 Eisai Co., Ltd. Fluorides of 4-substituted piperidine derivatives
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US20020151591A1 (en) 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
US7635709B2 (en) 2002-09-26 2009-12-22 The United States Of America As Represented By The Department Of Veterans Affairs Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction
AU2003274353B2 (en) 2002-10-24 2007-04-05 Merz Pharma Gmbh & Co. Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
CN101249091A (zh) 2002-11-22 2008-08-27 约翰斯·霍普金斯大学 治疗认知功能障碍的靶位
WO2005079779A1 (en) 2003-10-22 2005-09-01 Merz Pharma Gmbh & Co. Kgaa THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC Aß PEPTIDES IN AMYLOIDOPATHIES
MX2007004250A (es) * 2004-10-12 2007-06-12 Hoffmann La Roche Derivados de imidazo[1,5-a]triazolo[1,5-d]benzodiazepina para el tratamiento de trastornos cognitivos.
CA2584757C (en) * 2004-10-20 2012-07-03 F. Hoffmann-La Roche Ag Halogen substituted benzodiazepine derivatives
KR100923393B1 (ko) * 2004-12-14 2009-10-23 에프. 호프만-라 로슈 아게 Ｇａｂａ 수용체 조절제로서 테트라사이클릭이미다조-벤조다이아제핀
US20060205822A1 (en) 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
EP1924712B1 (en) 2005-08-03 2018-10-03 The Johns Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
EP2318005B1 (en) 2008-08-01 2017-11-01 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
CA2737452C (en) 2008-09-25 2018-05-22 Vive Nano Inc. Methods to produce polymer nanoparticles and formulations of active ingredients
CA2786716A1 (en) 2010-01-11 2011-07-14 Mithridion, Inc. Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
ES2711973T3 (es) * 2010-11-05 2019-05-08 Hoffmann La Roche Uso de compuestos farmacéuticos activos para el tratamiento de afecciones del sistema nervioso central
US20150374705A1 (en) * 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
AU2013312240A1 (en) 2012-09-10 2015-03-19 Ophirex Inc. Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade
CA3104478A1 (en) * 2018-06-19 2019-12-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
MX2022007725A (es) * 2019-12-19 2022-07-19 Agenebio Inc Derivados de benzodiazepinas, composiciones y metodos para tratar deterioro cognitivo.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5387585A (en) * 1991-06-17 1995-02-07 Hoffmann-La Roche Inc. Imidazodiazepine derivatives
CN1191255C (zh) * 2000-11-16 2005-03-02 弗·哈夫曼-拉罗切有限公司 作为gaba a受体调节剂的苯并二氮杂䓬衍生物
CN101044145A (zh) * 2004-10-20 2007-09-26 弗·哈夫曼-拉罗切有限公司 咪唑并－苯并二氮杂䓬衍生物
CN103327980A (zh) * 2010-11-15 2013-09-25 艾吉因生物股份有限公司 用于治疗认知障碍的苯并二吖庚因衍生物、组合物和方法
CN106068256A (zh) * 2013-12-20 2016-11-02 艾吉恩生物股份有限公司 用于治疗认知损害的苯并二氮杂*衍生物、组合物和方法
WO2016205739A1 (en) * 2015-06-19 2016-12-22 Belew Mekonnen Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GUIDO ACHERMANN ET AL.: ""Discovery of the imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4]benzodiazepine scaffold as a novel, potent and selective GABAA α5 inverse agonist series", 《BIOORG.MED.CHEM.LETT.》 *
MAX GERECKE ET AL.: "New tetracyclic derivatives of imidazo-[1,5-a][1,4]benzodiazepines and of imidazo-[1,5-a]thieno[3,2-f][1,4]diazepines", 《HETEROCYCLES》 *
MOHD.KAMIL HUSSAIN ET AL.: "Tandem C-2 functionalization-intramolecular azide-alkyne 1,3-dipolar cycloaddtion reaction: A convenient route to highly diversified 9H-benzo[b]pyrrolo[1,2-g][1,2,3]triazolo[1,5-d][1,4]diazepines", 《ORG.LETT》 *
OLIVER JONAS ET AL.: "First in vivo testing of compounds targeting group 3 medulloblastomas using an implantable microdevice as a new paradigm for drug development", 《J BIOMED NANOTECHNOL》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115175911A (zh) * 2019-12-19 2022-10-11 艾吉因生物股份有限公司 用于治疗认知损害的苯二氮䓬衍生物、组合物和方法
CN116457019A (zh) * 2020-07-10 2023-07-18 艾吉因生物股份有限公司 GABAAα5激动剂的多晶型物及其在治疗认知损害中的使用方法
CN113413532A (zh) * 2021-07-01 2021-09-21 曾迎春 基于虚拟现实的癌症相关认知障碍评估与康复训练系统
CN113413532B (zh) * 2021-07-01 2022-03-01 曾迎春 基于虚拟现实的癌症相关认知障碍评估与康复训练系统

Also Published As

Publication number Publication date
IL267451B1 (en) 2023-06-01
IL267451B2 (en) 2023-10-01
AU2017393082A1 (en) 2019-07-25
AU2017393082B2 (en) 2022-04-21
IL267451A (en) 2019-08-29
US20230134844A1 (en) 2023-05-04
MX2019007338A (es) 2019-09-19
MX388726B (es) 2025-03-20
NZ755287A (en) 2025-06-27
CA3047684A1 (en) 2018-07-19
EP3555100A4 (en) 2020-06-10
WO2018130868A8 (en) 2019-08-08
US20180170941A1 (en) 2018-06-21
WO2018130869A1 (en) 2018-07-19
EP3555100A1 (en) 2019-10-23
CN116640143A (zh) 2023-08-25
EP3555100B1 (en) 2023-05-10
JP7153938B2 (ja) 2022-10-17
WO2018130868A1 (en) 2018-07-19
EA201991497A1 (ru) 2020-01-20
JP2020512389A (ja) 2020-04-23

Similar Documents

Publication Publication Date Title
CN112601749B (zh) 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
CN106068256B (zh) 用于治疗认知损害的苯并二氮杂*衍生物、组合物和方法
CN110382501A (zh) 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
CN108026107B (zh) 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法
US11505555B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK40057489A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK40049071B (zh) 用於治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
HK40046882A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK40049071A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK40016541A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK1254362B (zh) 用於治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法
HK40016046B (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK40016046A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK1230171B (zh) 用於治疗认知损害的苯并二氮杂卓衍生物、组合物和方法
HK1230171A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40016541

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20191025

RJ01 Rejection of invention patent application after publication